Umlaut.Bio is a spinout of the EMBL, is pursuing tRNA targets for treatment of cancer and immunological diseases.
Umlaut.Bio has raised $3.5M in total funding. The most recent round was Pre-Seed. The last funding was announced in February 2026.
Umlaut.Bio's investors include Mission BioCapital, BaseLaunch.
Umlaut.Bio is headquartered in Heidelberg, Germany.
Umlaut.Bio is a spinout of the EMBL, is pursuing tRNA targets for treatment of cancer and immunological diseases.
Umlaut.Bio is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Umlaut.Bio — Funding & Investors." VCBacked, February 20, 2026, https://www.vcbacked.co/company/umlautbio. Accessed August 14, 2026.
VCBacked. (2026). Umlaut.Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/umlautbio
{{cite web |title=Umlaut.Bio — Funding & Investors |url=https://www.vcbacked.co/company/umlautbio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated